This comprehensive review traces GH secretagogue development from the first GHRP discovery through hexarelin, ipamorelin, MK-677, and ghrelin — covering two decades of peptide-to-drug translation.
Key findingGH secretagogue development spans from GHRP-6 discovery through systematic optimization (hexarelin, GHRP-2, ipamorelin for selectivity; MK-677 for ora
What the researchers found
GH secretagogue development spans from GHRP-6 discovery through systematic optimization (hexarelin, GHRP-2, ipamorelin for selectivity; MK-677 for oral activity) to ghrelin identification as the natural ligand — two decades of reverse pharmacology driving clinical drug development.
Why it matters
Relevant for ghrp, mk-677, hormone-optimization.
How the study worked
review study on ghrp, mk-677.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Development of growth hormone secretagogues.
Endocrine reviews, 26(3), 346-60
Citation
Smith, Roy G. (2005). Development of growth hormone secretagogues.. Endocrine reviews, 26(3), 346-60.